News

The PRISM clinical trial assesses 4D-150 (4D Molecular Therapeutics) in adults with neovascular age-related macular degeneration, also known as wet AMD.

In an analysis of the IRIS database, investigators assessed almost 1,200 eyes that had been treated with faricimab.

The LUMEOS phase 3 clinical trial resulted in botaretigene sparoparvovec not meeting primary endpoints to improve visual navigation of XLRP.

KIO-104 is a therapeutic candidate shown to significantly reduce retinal scar formation.

The VAN-2401 phase 1 clinical trial will evaluate the use of KH658 for the treatment of wet AMD.

4D-150 is a potential backbone therapy that is designed to provide multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) to be targeted to the retina with a single, well-tolerated intravitreal injection.

Lukas Scheibler, PhD, and Graham Cooper join Tavo Biotherapeutics and chief research and development officer and chief financial officer.

The OcuMet Beacon is a proprietary, noninvasive tool for assessing retinal health. The company said it will be available on the US market for use in clinics and healthcare institutions.

Prevent Blindness has declared May the second annual inherited retinal disease and genetic testing month, offering free resources on education and other awareness efforts.

A large international study reported a genetic link between schizophrenia and retinal status.

The company announced 27 abstracts at the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting from May 4 to 8 in Salt Lake City.

Topcon Healthcare has appointed Daniela Ferrara, MD, PhD, as chief medical officer to lead the company’s clinical and medical strategy.

A two-way foot bridge between eye care and mental health.

Brazilian researchers used swept-source OCT and OCT-angiography to study the effects of an initial dose of aflibercept on untreated diabetic macular edema in patients.

Five years after the COVID-19 pandemic shutdown reshaped how the world gathers, here's how some of ophthalmology’s leading associations are still applying lessons forged in crisis.

Industry leaders discuss the impact of rising tariffs on vision care costs, advocating for policy changes to ensure affordable access to essential eyewear.

Novel color created, olo, beyond previous human perception.

Abby Markward, MBA, executive director of the ASCRS Foundation and the ASOA, provides a sneak peek of the posterior segment-focused event.

Marsh will begin her role as COO April 28.

Authors defined metabolic syndrome as “the set of factors that increase the risk of cardiovascular disease and diabetes, such as hypertension, central obesity, insulin resistance, and atherogenic dyslipidemia.”

The FDA did not agree with a supplemental Biologics License Application for the addition of extended dosing intervals of up to 24 weeks across currently-approved indications.

Authors of the study believe this potential will provide clinicians with valuable information about patient responses to treatment.

The research team noted that racial subgroups are underrepresented in clinical trials, a factor that should be addressed in future clinical trials.

Companies working in the retina space have announced that data from clinical trials will be shared at this year’s meeting in Fort Lauderdale, Florida.

The sBLA seeks approval for Eylea HD for both the treatment of macular edema following retinal vein occlusion, and for broadening the dosing schedule to include every-4-week dosing across approved indications.